Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.
Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte Ad, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers. Palmisano L, et al. Among authors: vella s. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47. J Acquir Immune Defic Syndr. 2007. PMID: 17972364 Clinical Trial.
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G, Marazzi MC, Mancini MG, Cusato M, Germano P, Loureiro S, Ceffa S, Regazzi M, Vella S, Palombi L. Giuliano M, et al. Among authors: vella s. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):286-91. doi: 10.1097/QAI.0b013e31802c5441. J Acquir Immune Defic Syndr. 2007. PMID: 17146372 Clinical Trial.
Gender differences in the treatment of HIV infection.
Floridia M, Giuliano M, Palmisano L, Vella S. Floridia M, et al. Among authors: vella s. Pharmacol Res. 2008 Sep-Oct;58(3-4):173-82. doi: 10.1016/j.phrs.2008.07.007. Epub 2008 Jul 30. Pharmacol Res. 2008. PMID: 18708144 Review.
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
Pirillo M, Palmisano L, Pellegrini M, Galluzzo C, Weimer L, Bucciardini R, Fragola V, Andreotti M, Marchei E, Pichini S, Vella S, Giuliano M. Pirillo M, et al. Among authors: vella s. AIDS Res Hum Retroviruses. 2010 May;26(5):541-5. doi: 10.1089/aid.2009.0116. AIDS Res Hum Retroviruses. 2010. PMID: 20455761 Clinical Trial.
598 results